Compare · MMSI vs WST
MMSI vs WST
Side-by-side comparison of Merit Medical Systems Inc. (MMSI) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMSI and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.22B, about 5.8x MMSI ($3.85B).
- MMSI has been more active in the news (14 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (16 ratings vs 15 for MMSI).
- Company
- Merit Medical Systems Inc.
- West Pharmaceutical Services Inc.
- Price
- $64.51+2.32%
- $314.41-0.90%
- Market cap
- $3.85B
- $22.22B
- 1M return
- +4.65%
- -
- 1Y return
- -31.97%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 14
- 4
- Recent ratings
- 15
- 16
Merit Medical Systems Inc.
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest MMSI
- SEC Form SD filed by Merit Medical Systems Inc.
- Director Gunderson Thomas J. exercised 21,250 shares at a strike of $52.17, increasing direct ownership by 54% to 60,741 units (SEC Form 4)
- Director Ward Lynne N. was granted 3,457 shares, increasing direct ownership by 44% to 11,266 units (SEC Form 4)
- Director Ward Scott R. was granted 3,457 shares (SEC Form 4)
- Director Gunderson Thomas J. was granted 3,457 shares, increasing direct ownership by 10% to 39,491 units (SEC Form 4)
- Director Evans Stephen C. was granted 3,457 shares, increasing direct ownership by 51% to 10,266 units (SEC Form 4)
- Director Kaiser Laura S. was granted 3,457 shares, increasing direct ownership by 35% to 13,352 units (SEC Form 4)
- Director Perez Silvia M. was granted 3,457 shares, increasing direct ownership by 75% to 8,040 units (SEC Form 4)
- Director Carpenter Lonny J. was granted 3,457 shares, increasing direct ownership by 20% to 20,824 units (SEC Form 4)
- Director Mcdonnell Michael R. was granted 3,457 shares, increasing direct ownership by 54% to 9,852 units (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)